- Home
- ROIV vs CIEN Comparison
ROIV vs CIEN Comparison
Compare ROIV & CIEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ROIV | CIEN |
|---|---|---|
| Founded | 2014 | 1992 |
| Country | United Kingdom | United States |
| Employees | 721 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 60.7B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ROIV | CIEN |
|---|---|---|
| Price | $36.56 | $348.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $28.94 | ★ $382.69 |
| AVG Volume (30 Days) | ★ 8.6M | 2.3M |
| Earning Date | 05-28-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 46.55 |
| EPS | N/A | ★ 4.34 |
| Revenue | $8,260,000.00 | ★ $4,769,507,000.00 |
| Revenue This Year | N/A | $30.83 |
| Revenue Next Year | $744.61 | $19.87 |
| P/E Ratio | ★ N/A | $82.01 |
| Revenue Growth | N/A | ★ 18.79 |
| 52 Week Low | $14.86 | $138.12 |
| 52 Week High | $42.50 | $637.51 |
Technical Indicators
Market Signals| Indicator | ROIV | CIEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.86 | 46.49 |
| Support Level | $33.15 | $317.45 |
| Resistance Level | $37.12 | $365.90 |
| Average True Range (ATR) | 1.46 | 16.87 |
| MACD | -0.39 | 4.26 |
| Stochastic Oscillator | 30.86 | 57.92 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CIEN Ciena Corporation
Ciena is a leader in high-speed optical connectivity, providing systems, components, and automation software for telecom providers and enterprises, such as data centers, to enable long-distance connectivity. The company operates through four primary business segments: networking platforms, platform software and services, Blue Planet automation software, and global services. While telecom carriers remain important customers, cloud providers and hyperscalers now drive a significant portion of the business. To meet the demands of AI data centers, customers are adopting Ciena's WaveLogic 6 platform, the first to support 1.6 terabits-per-second capacity.